Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2012

Primary Completion Date

August 29, 2033

Study Completion Date

August 29, 2033

Conditions

Stargardt's Disease

Interventions

DRUG

Long term follow up in all patients who received SAR422459 in previous study TDU13583

Blood draw for the laboratory assessment

Trial Locations (2)

Investigational Site Number : 250001, Paris

Oregon Health and Science University Site Number : 840001, Portland